1. Academic Validation
  2. Targeting Death-Associated Protein Kinases for Treatment of Human Diseases: Recent Advances and Future Directions

Targeting Death-Associated Protein Kinases for Treatment of Human Diseases: Recent Advances and Future Directions

  • J Med Chem. 2023 Jan 26;66(2):1112-1136. doi: 10.1021/acs.jmedchem.2c01606.
Lan Zhang 1 Boqin Luo 1 Yingying Lu 1 Yi Chen 2
Affiliations

Affiliations

  • 1 Sichuan Engineering Research Center for Biomimetic Synthesis of Natural Drugs, School of Life Science and Engineering, Southwest Jiaotong University, Chengdu, Sichuan 610031, China.
  • 2 State Key Laboratory of Biotherapy and Cancer Center and Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
Abstract

The death-associated protein kinase (DAPK) family is a member of the calcium/calmodulin-regulated serine/threonine protein kinase family, and studies have shown that its role, as its name suggests, is mainly to regulate cell death. The DAPK family comprises five members, including DAPK1, DAPK2, DAPK3, DRAK1 and DRAK2, which show high homology in the common N-terminal kinase domain but differ in the extra-catalytic domain. Notably, previous research has suggested that the DAPK family plays an essential role in both the development and regulation of human diseases. However, only a few small-molecule inhibitors have been reported. In this Perspective, we mainly discuss the structure, biological function, and role of DAPKs in diseases and the currently discovered small-molecule inhibitors, providing valuable information for the development of the DAPK field.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-117364
    DAPK3 Inhibitor